Among three subtypes of PPARs, PPARα and PPARγ have been widely applied in clinic because the related drugs are already available for treating metabolic disease including type II diabetes and dyslipidemia (such as PPARα agonist fibrates and PPARγ agonist thiazolidinediones) [10]. Here, PPARA is linked to type 2 diabetes mellitus.